Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.
Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.
Nucleic Acids Res. 2024 Jan 5;52(D1):D1393-D1399. doi: 10.1093/nar/gkad1042.
Drug resistance is a major barrier in cancer treatment and anticancer drug development. Growing evidence indicates that non-coding RNAs (ncRNAs), especially microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), play pivotal roles in cancer progression, therapy, and drug resistance. Furthermore, ncRNAs have been proven to be promising novel therapeutic targets for cancer treatment. Reversing dysregulated ncRNAs by drugs holds significant potential as an effective therapeutic strategy for overcoming drug resistance. Therefore, we developed ncRNADrug, an integrated and comprehensive resource that records manually curated and computationally predicted ncRNAs associated with drug resistance, ncRNAs targeted by drugs, as well as potential drug combinations for the treatment of resistant cancer. Currently, ncRNADrug collects 29 551 experimentally validated entries involving 9195 ncRNAs (2248 miRNAs, 4145 lncRNAs and 2802 circRNAs) associated with the drug resistance of 266 drugs, and 32 969 entries involving 10 480 ncRNAs (4338 miRNAs, 6087 lncRNAs and 55 circRNAs) targeted by 965 drugs. In addition, ncRNADrug also contains associations between ncRNAs and drugs predicted from ncRNA expression profiles by differential expression analysis. Altogether, ncRNADrug surpasses the existing related databases in both data volume and functionality. It will be a useful resource for drug development and cancer treatment. ncRNADrug is available at http://www.jianglab.cn/ncRNADrug.
耐药性是癌症治疗和抗癌药物开发的主要障碍。越来越多的证据表明，非编码 RNA（ncRNA），特别是 microRNAs（miRNAs）、长非编码 RNA（lncRNAs）和环状 RNA（circRNAs），在癌症进展、治疗和耐药性中发挥关键作用。此外，已经证明 ncRNA 是癌症治疗有前途的新型治疗靶点。通过药物逆转失调的 ncRNA 作为克服耐药性的有效治疗策略具有重要潜力。因此，我们开发了 ncRNADrug，这是一个集成和全面的资源，记录了与耐药性相关的经过人工 curated 和计算预测的 ncRNA、药物靶向的 ncRNA 以及治疗耐药性癌症的潜在药物组合。目前，ncRNADrug 收集了 29551 个经过实验验证的条目，涉及 9195 个 ncRNA（2248 个 miRNAs、4145 个 lncRNAs 和 2802 个 circRNAs）与 266 种药物的耐药性相关，以及 32969 个条目涉及 10480 个 ncRNA（4338 个 miRNAs、6087 个 lncRNAs 和 55 个 circRNAs）由 965 种药物靶向。此外，ncRNADrug 还包含通过差异表达分析从 ncRNA 表达谱中预测的 ncRNA 与药物之间的关联。总之，ncRNADrug 在数据量和功能方面都超过了现有的相关数据库。它将成为药物开发和癌症治疗的有用资源。ncRNADrug 可在 http://www.jianglab.cn/ncRNADrug 上获得。
Zotero 插件
